New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 5, 2014
09:29 EDTRAREUltragenyx announces license agreement with UniQuest, new U.S. patent
Ultragenyx Pharmaceutical announced a license agreement with UniQuest Pty Limited for intellectual property related to the treatment of refractory epilepsy and other seizure-related and neurologic disorders with triheptanoin. The intellectual property originated from research on epilepsy and other neurologic models conducted at The University of Queensland. Separately, a United States patent has been issued with claims directed to compositions of triheptanoin above a certain level of purity. The patent term expires in October 2025. A second U.S. patent with claims directed to compositions of triheptanoin in a dosage unit was issued in August 2013 and expires in June 2020. These patent terms do not include any potential for patent term extension of up to five additional years. Similar claims are either granted or being pursued by Ultragenyx in other territories outside the U.S.
News For RARE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 23, 2015
09:04 EDTRAREUltragenyx granted additional ODD for triheptanoin
Subscribe for More Information
April 22, 2015
07:41 EDTRAREUltragenyx announces positive data from triheptanoin trial
Subscribe for More Information
April 20, 2015
07:18 EDTRAREAmerican Academy of Neurology to hold annual meeting
Subscribe for More Information
April 16, 2015
09:10 EDTRAREUltragenyx granted orphan status for fatty acid disorders treatment
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use